Citius Oncology, Inc. SEC filings CTOR

Citius Oncology, Inc. has 268 filings in SEC EDGAR's recent list, going back to May 19, 2021. Its latest annual report, Form ARS, was filed on Aug 26, 2026 for the period ended Sep 30, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (other events). The company's fiscal year ends on September 30.

Form Description Filed Period
DEF 14A Proxy statement Aug 26, 2026 Sep 29, 2026
DEF 14C Information statement May 29, 2026 May 29, 2026
PRE 14C Preliminary information statement May 19, 2026 May 19, 2026
DEF 14C Information statement Jan 29, 2026 Jan 29, 2026
PRE 14C Preliminary information statement Jan 20, 2026 Jan 20, 2026
DEF 14A Proxy statement Sep 26, 2025 Oct 27, 2025
DEF 14C Information statement Feb 24, 2025 Feb 24, 2025
PRE 14C Preliminary information statement Feb 12, 2025 Feb 12, 2025
DEFA14A Additional proxy material Jan 10, 2024 —
DEF 14A Proxy statement Jan 8, 2024 Jan 8, 2024
PRE 14A Preliminary proxy statement Dec 28, 2023 Dec 28, 2023

Showing 11 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
CTOR (Nasdaq)
Fiscal year ends
September 30
Incorporated in
DE
Headquarters
Cranford, NJ
SEC filer status
, Emerging growth company
SEC CIK
1851484
Former names
TenX Keane Acquisition (until Aug 5, 2024)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.